News
CABA
2.190
+1.39%
0.030
William Blair Remains a Buy on Cabaletta Bio (CABA)
TipRanks · 1d ago
Cabaletta Bio Advances Clinical Trials with Lonza Partnership
TipRanks · 1d ago
Cabaletta Bio announces strategic priorities, anticipated milestones for 2025
TipRanks · 1d ago
CABALETTA BIO : EXPECTS CASH POSITION AS OF DEC 31, 2024, WILL ENABLE IT TO FUND ITS UPDATED OPERATING PLAN INTO FIRST HALF OF 2026
Reuters · 1d ago
CABALETTA BIO INC: UNAUDITED CASH AND CASH EQUIVALENTS AS OF DEC 31, 2024 WAS $164 MLN
Reuters · 1d ago
Cabaletta Bio Outlines 2025 Milestones, Plans Meeting With FDA On Rese-cel Trial Designs, Favorable Safety With 90% Patients Showing No Significant Side Effects, First Enrollments In RESET-PV And RESET-Myositis Trials, IND Cleared For RESET-MS With Fast Track Status
Benzinga · 1d ago
CABALETTA BIO INC - CABALLETTA TO MEET FDA ON RESE-CEL TRIAL DESIGNS IN 1H25
Reuters · 1d ago
CABALETTA BIO OUTLINES STRATEGIC PRIORITIES AND ANTICIPATED KEY MILESTONES FOR 2025
Reuters · 1d ago
Weekly Report: what happened at CABA last week (0106-0110)?
Weekly Report · 2d ago
Cabaletta Bio: Finding Optimism In Dire Straits
Seeking Alpha · 01/06 19:28
Looking Into Cabaletta Bio's Recent Short Interest
Benzinga · 01/06 13:45
Weekly Report: what happened at CABA last week (1230-0103)?
Weekly Report · 01/06 09:02
Weekly Report: what happened at CABA last week (1223-1227)?
Weekly Report · 12/30/2024 09:01
Weekly Report: what happened at CABA last week (1216-1220)?
Weekly Report · 12/23/2024 09:01
Analysts Conflicted on These Healthcare Names: Verastem (VSTM), Roche Holding AG (OtherRHHVF) and Cabaletta Bio (CABA)
TipRanks · 12/20/2024 17:20
Cabaletta Bio Cut to In-Line From Outperform by Evercore ISI Group
Dow Jones · 12/20/2024 11:47
Cabaletta Bio Price Target Cut to $6.00/Share From $15.00 by Evercore ISI Group
Dow Jones · 12/20/2024 11:47
Evercore ISI Group Downgrades Cabaletta Bio to In-Line, Lowers Price Target to $6
Benzinga · 12/20/2024 11:37
Cabaletta Bio downgraded at Evercore ISI on lack of financing clarity
TipRanks · 12/20/2024 11:21
Cabaletta Bio downgraded to In Line from Outperform at Evercore ISI
TipRanks · 12/20/2024 10:45
More
Webull provides a variety of real-time CABA stock news. You can receive the latest news about Cabaletta Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.